Clostridium difficile in paediatric populations

Paediatrics and Child Health (Canada)

Volumn 19, Issue 1, 2014, Pages 43-48

  Allen, Upton D ^a   Bortolussi, Robert ^a   Bridger, Natalie A ^a   Finlay, Jane C ^a   Martin, Susanna ^a   McDonald, Jane C ^a   Onyett, Heather ^a   Robinson, Joan L ^a   Salvadori, Marina I ^a   Vanderkooi, Otto G ^a  

^a NONE

Author keywords

CDI; Colitis; Diarrhea; Immunocompromise; Megacolon; Metronidazole; NAP1; Vancomycin

Indexed keywords

ALCOHOL; ANION EXCHANGE RESIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BACITRACIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM TOXIN; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; FUSIDIC ACID; GLUTAMATE DEHYDROGENASE; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAXIMIN; TEICOPLANIN; TINIDAZOLE; VANCOMYCIN;

AGE DISTRIBUTION; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CHILD CARE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIARRHEA; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FECES ANALYSIS; GASTROINTESTINAL SURGERY; HAND WASHING; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PSEUDOMEMBRANOUS COLITIS; RECURRENCE RISK; RECURRENT INFECTION; REVIEW; UNITED STATES;

EID: 84892595561     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/19.1.43     Document Type: Review

References (79)

1. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346(5):334-9.
2. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;59(18):1932-40.
3. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981;81(1):5-9.
4. Cerquetti M, Luzzi I, Caprioli A, Sebastianelli A, Mastrantonio P. Role of Clostridium difficile in childhood diarrhea. Pediatr Infect Dis J 1995;14(7):598-603.
5. Lamont JT. Theodore E. Woodward Award: How bacterial enterotoxins work; Insights from in vivo studies. Trans Am Clin Climatol Assoc 2002;113:167-80.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31(5):431-55: http://www.cdc.gov/HAI/pdfs/cdiff/Cohen-IDSA-SHEA-CDIguidelines-2010.pdf (Accessed October 30, 2013).
7. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320(4):204-10.
8. Toshniwal R, Silva J Jr, Fekety R, Kim KH. Studies on the epidemiology of colitis due to Clostridium difficile in hamsters. J Infect Dis 1981;143(1):51-4.
9. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis 1994;18(2):181-7.
10. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986;146(1): 95-100.
11. Nylund CM, Goudie A, Garza JM, Fairbrother G, Cohen MB. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011;165(5):451-7.
12. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaotis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122(6);1266-70.
13. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004;171(5):466-72.
14. Kim J, Shaklee JF, Smathers S, et al. Risk factors and outcomes associated with severe Clostridium difficile infection in children. Pediatr Infect Dis J 2012;31(2):134-8.
15. Rengel SJ, Fung M, Graham DA, Ma L, Nelson CP, Sandora TJ. Recent trends in the use of antibiotic prophylaxis in pediatric surgery. J Pediatr Surg 2011;46(2):366-71.
16. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341(22):1645-51.
17. Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005;41(11):1621-27.
18. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351(9103):633-6.
19. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000;342(6):390-7.
20. Muñoz P, Giannella M, Alcalá L, et al. Clostridium difficile-associated diarrhea in heart transplant recipients: Is hypogammaglobulinemia the answer? J Heart Lung Transplant 2007;26(9):907-14.
21. Wolfhagen MJ, Meijer K, Fluit AC, et al. Clinical significance of Clostridium difficile and its toxins in faeces of immunocompromized children. Gut 1994;35(11):1608-12.
22. Thibault A, Miller MA, Gaese C. Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak. Infect Control Hosp Epidemiol 1991;12(6):345-8.
23. Bliss DZ, Johnson S, Savik K, et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998;129(12):1012-9.
24. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26(3):273-80.
25. Dial S, Delaney JA, Barkun AN, Suisse S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989-95.
26. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54(3):243-5.
27. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004;171(1):33-8.
28. Al-Jumaili IJ, Shibley M, Lishman AH, Record CO. Incidence and origin of Clostridium difficile in neonates. J Clin Microbiol 1984;19(1):77-8.
29. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353(23):2442-9.
30. Pépin J, Valiquette L, Alary ME, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40(11):1591-7.
31. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93(3):175-81.
32. Rexach CE, Tang-Feldman Y, Cantrell MC, Cohen SH. Epidemiologic surveillance of Clostridium difficile diarrhea in a freestanding pediatric hospital and a pediatric hospital at a university medical center. Diagn Microbiol Infect Dis 2006;56(2):109-14.
33. Gould CV, McDonald CL. Bench-to-bedside review: Clostridium difficile colitis. Crit Care 2008;12(1):203.
34. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433-41.
35. Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs), Clostridium difficile infection: http://www.cdc.gov/HAI/ organisms/cdiff/Cdiff-infect.html (Accessed October 30, 2013).
36. Eggertson L. Quebec strain of C. difficile in 7 provinces. CMAJ 2006;174(5):607-8.
37. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366(9491):1079-84.
38. Health Protection Agency. Outbreak of Clostridium difficile infection in a hospital in southeast England. CDR Weekly 2005;15(24).
39. Kuijper EJ, van den Berg RJ, Debast SB, et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis 2006;12(5):827-30.
40. Kuijper EJ, Barbut F, Brazier JS, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;13(31):pii:18942.
41. Kato H, Ito Y, van den Berg RJ, Kuijper EJ, Arakawa Y. First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007;12(1):E070111.3.
42. Toltzis P, Kim J, Dul M, Zoltanski J, Smathers S, Zaoutis T. Presence of the epidemic North American Pulsed Field type 1 Clostridium difficile strain in hospitalized children. J Pediatr 2009;154(4):607-8.
43. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007;35(4):237-53.
44. Tamma PD, Sandora TJ. Clostridium difficile infection in children: Current state and unanswered questions. J Pediatric Infect Dis Soc 2012;1(3):230-243.
45. Miller M, Gravel D, Mulvey M. Health care-associated Clostridium difficile infection in Canada: Patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis; 2005;50(2):194-201.
46. Laino C. C. diff on rise in kids - and outside hospital: Study shows cases of dangerous diarrhea bug increased 12-fold among children. Based on presentation by S. Khanna for Digestive Disease Week 2012 in San Diego: http://children.webmd.com/news/20120521/c-diff-on-rise-in-kidsand-outside- hospital (Accessed October 31, 2013).
47. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171(1):51-8
48. American Academy of Pediatrics. Clostridium difficile. In: Pickering LK, Backer CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infections Diseases, 29th edn. Elk Grove Village: American Academy of Pediatrics, 2012:285-7.
49. Debast SB, Bauer MP, Kuijper EJ; The Committee. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2013 October 5. doi: 10.1111/1469-0691.12418. [Epub ahead of print].
50. Staneck JL, Weckbach LS, Allen SD, et al. Multicenter evaluation of four methods for Clostridium difficile detection: ImmunoCard C. difficile, cytotoxin assay, culture, and latex agglutination. J Clin Microbiol 1996;34(11):2718-21.
51. Snell H, Ramos M, Longo S, John M, Hussain Z. Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea. J Clin Microbiol 2004;42(10):4863-5.
52. Zheng L, Keller SF, Lyerly DM, et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol 2004;42(8):3837-40.
53. Stamper PD, Alcabasa R, Aird D, et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 2009;47(2):373-8.
54. Deshpande A, Pasupuleti V, Rolston DD, et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: A meta-analysis. Clinical Infect Dis 2011;53(7):e81-e90.
55. Public Health Ontario, Provincial Infectious Diseases Advisory Committee, 2013.Annex C: Testing, surveillance and management of Clostridium difficile in all health care settings: http://www.publichealthontario.ca/en/eRepository/ PIDACIPC-Annex-C-Testing-SurveillanceManage-C-difficile-2013.pdf (Accessed November 13, 2013).
56. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis. JAMA 2012;307(18):1959-69.
57. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012;(4)7:e34938.
58. Johnston BC, Ma SS, Goldenburg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Ann Int Med 2012;157(12):878-88.
59. Marchand V; Canadian Paediatric Society, Nutrition and Gastroenterology Committee. Using probiotics in the paediatric population. Paediatr Child Health 2012;17(10):575: http://www.cps.ca/en/documents/position/probiotics-in-the- paediatric-population (Accessed October 31, 2013).
60. Aslam S, Musher DM. An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. Gastroentrol Clin North Am 2006;35(2):315-35.
61. Barbut F, Richard A, Hamadi K, Chomette V, Burghoffer B, Petit JC. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 2000;38(6):2386-8.
62. Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: A prospective study. Int J Clin Pharmacol Res 1999;19(3):83-8.
63. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44(6):846-8.
64. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009;48(4):425-9.
65. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271(24):1913-8.
66. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: A comprehensive review. Clin Infect Dis 2005;41(11):1559-68.
67. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; (3):CD004610.
68. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22(5):813-8.
69. Wullt M, Odenholt I. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J Antimicrob Chemother 2004;54:211-16.
70. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomized controlled trial. Lancet Infect Dis 2012;12(4):281-9.
71. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364(5):422-31.
72. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003;36(5):580-5.
73. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011;53(10):994-1002.
74. van Nood E, Vrieza A, Nieuwdrop M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368(5):407-15.
75. Russell G, Kaplan J, Ferraro M, Michelow IC. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: A proposed treatment protocol. Pediatrics 2010;126(1):e239-42.
76. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013;1:3.
77. Aboudola S, Kotloff KL, Kyne L, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003;71(3):1608-10.
78. Gerding DN. Clostridium difficile infection prevention: Biotherapeutics, immunologies, and vaccines. Discov Med 2012;13(68):75-83: http://www. discoverymedicine.com/Dale-N-Gerding/2012/01/25/clostridium-difficile-infection- prevention-biotherapeutics-immunologics-and-vaccines/ (Accessed November 13, 2013).
79. Sanofi Pasteur initiates phase III study of investigational vaccine in Canada to prevent Clostridium difficile: http://www.sanofipasteur.ca/node/40701 (Accessed November 13, 2013).